Good news from Kintor Pharma on their KX-826 topical anti-androgen trial for hair loss. The pharmaceutical company has been making steady progress and is now officially in phase III trial in China for male pattern baldness.
Phase II trial in the US has also begun.
This is going to be a game changer for hair loss as we will very likely have 3 proven treatments for hair loss or androgenetic alopecia in the very near future, namely:
1. Topical Minoxidil - works as vasodilator or for enhancing blood circulation + other mechanisms that are beneficial for hair regrowth
2. Oral Finasteride - 5 alpha reductase inhibitory to reduce DHT in our body
3. KX826 - topical anti-androgen
See below excerpt from Kintor’s website for product timeline:
Synopsis of phase II trial results can be found at Kintor Pharma Announces 2022 Interim Results and Recent Business Highlights_Kintor Pharmaceutical Limited
Press about phase II trial can be found at Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US_Kintor Pharmaceutical Limited
This is an update from our prevoious coverage on this product for those who wish to revisit Kintor Pharma KX-826 (pyrilutamide) topical androgen receptor inhibitor for hair loss, phase II trial primary endpoint met
Hasson & Wong sponsored post - #1 hair clinic in Canada and Top 3 clinics of all time in the world according to HairSite’s patient statistics. For more info, visit: